Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL), to Compare Outcomes to Those From Tafasitamab + Lenalidomide in the L-MIND Study

X
Trial Profile

An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL), to Compare Outcomes to Those From Tafasitamab + Lenalidomide in the L-MIND Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Tafasitamab (Primary) ; Bendamustine; Polatuzumab vedotin; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms RE-MIND2
  • Sponsors MorphoSys
  • Most Recent Events

    • 13 Dec 2022 Results of post hoc sub-analysis (n=109) assessing the disease landscape, real-world patients characteristics, and current management of Canadian patients enrolled in the RE-MIND2 study, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 09 Nov 2022 Results of post hoc analysis of the RE-MIND2 Study Comparing Multiple Cohort-Balancing Approaches , presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 01 Oct 2022 Results assessing relative effectiveness of tafasitamab+lenalidomide versus other treatments for relapsed/refractory diffuse large B-cell lymphoma in clinically relevant patient subgroups in the absence of head-to-head trials, published in the Clinical Lymphoma, Myeloma & Leukemia.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top